AMPLICONYX OY

Their core work

Ampliconyx Oy is a Finnish photonics SME based in Tampere specialising in advanced fiber laser systems — specifically tapered double-clad fiber architectures capable of producing high-power ultrafast laser pulses. Their core engineering competence lies in designing and building precision laser hardware, from the fiber waveguide geometry through to scanning and imaging optics. Beyond industrial laser development, they have applied this photonics expertise to biomedical imaging, contributing specialist knowledge to multi-photon endoscopy tools for real-time clinical histology and bladder cancer diagnosis. In both contexts, their value to a consortium is deep photonic component and system know-how rather than project management or platform integration.

What they specialise in

How they've shifted over time

Their first H2020 project (PULSE, 2019) was squarely in laser hardware development for industrial use — tapered fiber laser architecture, polygon scanning optics, and nano-imprint lithography aimed at automotive applications. By 2020, in AMPLITUDE, the same underlying fiber laser and photonics competence was redirected toward a completely different domain: clinical medicine, specifically multi-photon endoscopic imaging for real-time bladder cancer diagnosis. The trajectory is a deliberate pivot from industrial laser engineering toward medical photonics, with the core technology (ultrafast fiber lasers) remaining constant while the application domain shifted from factory floor to operating theatre.

Ampliconyx appears to be repositioning their ultrafast laser expertise into the clinical diagnostics market, suggesting future collaborations are most likely in biophotonics, minimally invasive imaging, and medical device development rather than industrial laser manufacturing.

How they like to work

Ampliconyx has participated exclusively as a consortium partner in both projects, never taking on a coordinator role — consistent with a specialist SME that contributes deep technical expertise rather than project management capacity. Despite only two projects, they have accumulated 19 unique consortium partners across 9 countries, pointing to participation in large, multi-partner RIA consortia rather than tight bilateral arrangements. This suggests they are recruited for a specific photonic technology niche and plug into broader consortia built around clinical or industrial applications.

With 19 unique partners across 9 countries from only two projects, Ampliconyx has built a surprisingly broad European network relative to their project volume. Their collaborations span research institutions and industry partners across multiple EU member states, reflecting the cross-disciplinary nature of both laser engineering and biomedical imaging consortia.

What sets them apart

Ampliconyx occupies a rare intersection: an SME with hands-on fiber laser fabrication capability that has also demonstrated credibility in clinical medical imaging — two domains that rarely share the same partner profile. Most photonics SMEs stay in either the industrial or the medical channel; Ampliconyx has proven they can contribute in both, making them attractive to consortia that need a laser hardware specialist who understands clinical constraints. Being based in Tampere, a recognised Finnish photonics and optics cluster, also places them within a strong regional innovation ecosystem for follow-on partnerships.

Highlights from their portfolio

• PULSE
  Their largest funded project (€1.1M EC contribution), focused on developing next-generation high-power ultrafast fiber lasers with tapered double-clad architecture — representing the core laser hardware competence from which all their other work derives.
• AMPLITUDE
  Marks a significant application pivot: using fiber laser expertise to build a multi-photon endoscopic imaging tool for real-time bladder cancer diagnosis in clinical settings, bridging photonics engineering with oncology diagnostics.